Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
暂无分享,去创建一个
C. Tournigand | M. Buyse | I. Chirivella | A. Figer | F. Rivera | T. Burzykowski | J. Abrahantes | L. Mineur | A. de Gramont | A. Cervantes | T. André | I. Tabah-Fisch | C. Louvet | E. Quinaux | G. Lledo | M. Flesch | P. Etienne | E. Carola | N. Perez-staub
[1] C. Tournigand,et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Sargent,et al. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Tournigand,et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[5] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[6] D. Sargent,et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Buyse,et al. Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Daniel J Sargent,et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[11] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[13] M Buyse,et al. On the relationship between response to treatment and survival time. , 1996, Statistics in medicine.
[14] Raymond J. Carroll,et al. Asymptotics for the SIMEX Estimator in Nonlinear Measurement Error Models , 1996 .
[15] J. R. Cook,et al. Simulation-Extrapolation Estimation in Parametric Measurement Error Models , 1994 .
[16] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[17] David A. Schoenfeld,et al. Partial residuals for the proportional hazards regression model , 1982 .
[18] D. Cox. Regression Models and Life-Tables , 1972 .
[19] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .